Alternative 5‐Azacitidine 5‐Day 100 mg/m <sup>2</sup> Dosage Shows Non‐Inferiority to Classical Schedule for Myelodysplastic Neoplasm (MDS) and Chronic Myelomonocytic Leukaemia (CMML) Treatment
Authors
- Γεράσιμος Τσιλιμιδός (ORCID: https://orcid.org/0000-0002-0416-8420)
- Mariangela Costanza (ORCID: https://orcid.org/0000-0003-1824-9886)
- Filipe Martins (ORCID: https://orcid.org/0000-0002-3096-8907)
- Sabine Blum (ORCID: https://orcid.org/0000-0003-2275-3081)
- Mathilde Gavillet (ORCID: https://orcid.org/0000-0002-2485-8197)
Institutions
- Fribourg Development Agency (CH)
- École Polytechnique Fédérale de Lausanne (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- eJHaem
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1002/jha2.70185
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00